AstraZeneca Report Results of Brilinta (ticagrelor) in P-III THALES Study for Patients with Acute Ischemic Stroke or Transient Ischemic Attack

 AstraZeneca Report Results of Brilinta (ticagrelor) in P-III THALES Study for Patients with Acute Ischemic Stroke or Transient Ischemic Attack

AstraZeneca Reports Results of Brilinta (ticagrelor) in P-III THALES Study for Patients with Minor Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Shots:

  • The P-III THALES study involves assessing of Brilinta (180mg as a loading dose followed by 90mg, bid) + aspirin vs aspirin as monothx. in 11,000 patients with non-cardioembolic acute ischaemic stroke or high-risk TIA for 30days
  • Results: 17% reduction in 1EPs of stroke and death, 21% reduction in 2EPs of ischaemic stroke, the risk for severe bleeding events (0.1% vs 0.5%); results were consistent with the known safety profile of Brilinta
  • Brilinta is approved in 110+ countries to prevent atherothrombotic events in adult patients with ACS and in 70+ countries for the secondary prevention of CV events among high-risk patients experienced a heart attack. In May’2020, the FDA approved a label update for Brilinta in the US to include the reduction of the risk of a first heart attack or stroke in high-risk patients with CAD

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: CNBC

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post